Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 11 of 11 entries
Sorted by: Best Match Show Resources per page
Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver.

Hepatology communications

Schulze RJ, Drižytė K, Casey CA, McNiven MA.
PMID: 29109982
Hepatol Commun. 2017 Jul;1(5):359-369. doi: 10.1002/hep4.1056. Epub 2017 Jun 09.

The liver is a central fat-storage organ, making it especially susceptible to steatosis as well as subsequent inflammation and cirrhosis. The mechanisms by which the liver mobilizes stored lipid for energy production, however, remain incompletely defined. The catabolic process...

Cite
Schulze RJ, Drižytė K, Casey CA, et al. Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver. Hepatol Commun. 2017;1(5):359-369doi: 10.1002/hep4.1056.
Schulze, R. J., Drižytė, K., Casey, C. A., & McNiven, M. A. (2017). Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver. Hepatology communications, 1(5), 359-369. https://doi.org/10.1002/hep4.1056
Schulze, Ryan J, et al. "Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver." Hepatology communications vol. 1,5 (2017): 359-369. doi: https://doi.org/10.1002/hep4.1056
Schulze RJ, Drižytė K, Casey CA, McNiven MA. Hepatic Lipophagy: New Insights into Autophagic Catabolism of Lipid Droplets in the Liver. Hepatol Commun. 2017 Jul;1(5):359-369. doi: 10.1002/hep4.1056. Epub 2017 Jun 09. PMID: 29109982; PMCID: PMC5669271.
Copy Download .nbib Format: NLM
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.

PLoS medicine

Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D.
PMID: 34928960
PLoS Med. 2021 Dec 20;18(12):e1003872. doi: 10.1371/journal.pmed.1003872. eCollection 2021 Dec.

BACKGROUND: The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized...

Cite
Senefeld JW, Johnson PW, Kunze KL, et al. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021;18(12):e1003872doi: 10.1371/journal.pmed.1003872.
Senefeld, J. W., Johnson, P. W., Kunze, K. L., Bloch, E. M., van Helmond, N., Golafshar, M. A., Klassen, S. A., Klompas, A. M., Sexton, M. A., Diaz Soto, J. C., Grossman, B. J., Tobian, A. A. R., Goel, R., Wiggins, C. C., Bruno, K. A., van Buskirk, C. M., Stubbs, J. R., Winters, J. L., Casadevall, A., Paneth, N. S., Shaz, B. H., Petersen, M. M., Sachais, B. S., Buras, M. R., Wieczorek, M. A., Russoniello, B., Dumont, L. J., Baker, S. E., Vassallo, R. R., Shepherd, J. R. A., Young, P. P., Verdun, N. C., Marks, P., Haley, N. R., Rea, R. F., Katz, L., Herasevich, V., Waxman, D. A., Whelan, E. R., Bergman, A., Clayburn, A. J., Grabowski, M. K., Larson, K. F., Ripoll, J. G., Andersen, K. J., Vogt, M. N. P., Dennis, J. J., Regimbal, R. J., Bauer, P. R., Blair, J. E., Buchholtz, Z. A., Pletsch, M. C., Wright, K., Greenshields, J. T., Joyner, M. J., Wright, R. S., Carter, R. E., & Fairweather, D. (2021). Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS medicine, 18(12), e1003872. https://doi.org/10.1371/journal.pmed.1003872
Senefeld, Jonathon W, et al. "Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study." PLoS medicine vol. 18,12 (2021): e1003872. doi: https://doi.org/10.1371/journal.pmed.1003872
Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021 Dec 20;18(12):e1003872. doi: 10.1371/journal.pmed.1003872. eCollection 2021 Dec. PMID: 34928960; PMCID: PMC8730442.
Copy Download .nbib Format: NLM
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.

Frontiers in medicine

Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ.
PMID: 34164419
Front Med (Lausanne). 2021 Jun 07;8:684151. doi: 10.3389/fmed.2021.684151. eCollection 2021.

Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global usage, uncertainty remains regarding plasma efficacy, as randomized controlled trials (RCTs) have provided divergent evidence regarding the survival...

Cite
Klassen SA, Senefeld JW, Senese KA, et al. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021;8:684151doi: 10.3389/fmed.2021.684151.
Klassen, S. A., Senefeld, J. W., Senese, K. A., Johnson, P. W., Wiggins, C. C., Baker, S. E., van Helmond, N., Bruno, K. A., Pirofski, L. A., Shoham, S., Grossman, B. J., Henderson, J. P., Wright, R. S., Fairweather, D., Paneth, N. S., Carter, R. E., Casadevall, A., & Joyner, M. J. (2021). Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in medicine, 8684151. https://doi.org/10.3389/fmed.2021.684151
Klassen, Stephen A, et al. "Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence." Frontiers in medicine vol. 8 (2021): 684151. doi: https://doi.org/10.3389/fmed.2021.684151
Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021 Jun 07;8:684151. doi: 10.3389/fmed.2021.684151. eCollection 2021. PMID: 34164419; PMCID: PMC8215127.
Copy Download .nbib Format: NLM
Heat Versus Altitude Training for Endurance Performance at Sea Level.

Exercise and sport sciences reviews

Baranauskas MN, Constantini K, Paris HL, Wiggins CC, Schlader ZJ, Chapman RF.
PMID: 33044330
Exerc Sport Sci Rev. 2021 Jan;49(1):50-58. doi: 10.1249/JES.0000000000000238.

Environmental stressors, such as heat or altitude, elicit dissimilar physiological adaptations to endurance training programs. Whether these differences (i.e., increased hemoglobin mass vs plasma volume) differentially influence performance is debated. We review data in support of our novel hypothesis,...

Cite
Baranauskas MN, Constantini K, Paris HL, et al. Heat Versus Altitude Training for Endurance Performance at Sea Level. Exerc Sport Sci Rev. 2021;49(1):50-58doi: 10.1249/JES.0000000000000238.
Baranauskas, M. N., Constantini, K., Paris, H. L., Wiggins, C. C., Schlader, Z. J., & Chapman, R. F. (2021). Heat Versus Altitude Training for Endurance Performance at Sea Level. Exercise and sport sciences reviews, 49(1), 50-58. https://doi.org/10.1249/JES.0000000000000238
Baranauskas, Marissa N, et al. "Heat Versus Altitude Training for Endurance Performance at Sea Level." Exercise and sport sciences reviews vol. 49,1 (2021): 50-58. doi: https://doi.org/10.1249/JES.0000000000000238
Baranauskas MN, Constantini K, Paris HL, Wiggins CC, Schlader ZJ, Chapman RF. Heat Versus Altitude Training for Endurance Performance at Sea Level. Exerc Sport Sci Rev. 2021 Jan;49(1):50-58. doi: 10.1249/JES.0000000000000238. PMID: 33044330.
Copy Download .nbib Format: NLM
Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans.

Clinical medicine insights. Circulatory, respiratory and pulmonary medicine

Taylor NE, Baker SE, Olson TP, Lalande S, Johnson BD, Snyder EM.
PMID: 27773996
Clin Med Insights Circ Respir Pulm Med. 2016 Oct 12;10:19-25. doi: 10.4137/CCRPM.S30251. eCollection 2016.

BACKGROUND: Beta-2 adrenergic receptors (βMETHODS: We assessed the diffusing capacity of the lungs for carbon monoxide (DLCO) and nitric oxide (DLNO) at baseline, 30 minutes, and 60 minutes following nebulized albuterol (2.5 mg, diluted in 3 mL normal saline)...

Cite
Taylor NE, Baker SE, Olson TP, et al. Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans. Clin Med Insights Circ Respir Pulm Med. 2016;10:19-25doi: 10.4137/CCRPM.S30251.
Taylor, N. E., Baker, S. E., Olson, T. P., Lalande, S., Johnson, B. D., & Snyder, E. M. (2016). Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans. Clinical medicine insights. Circulatory, respiratory and pulmonary medicine, 1019-25. https://doi.org/10.4137/CCRPM.S30251
Taylor, Natalie E, et al. "Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans." Clinical medicine insights. Circulatory, respiratory and pulmonary medicine vol. 10 (2016): 19-25. doi: https://doi.org/10.4137/CCRPM.S30251
Taylor NE, Baker SE, Olson TP, Lalande S, Johnson BD, Snyder EM. Albuterol Improves Alveolar-Capillary Membrane Conductance in Healthy Humans. Clin Med Insights Circ Respir Pulm Med. 2016 Oct 12;10:19-25. doi: 10.4137/CCRPM.S30251. eCollection 2016. PMID: 27773996; PMCID: PMC5063752.
Copy Download .nbib Format: NLM
Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.

Frontiers in endocrinology

Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS.
PMID: 34777255
Front Endocrinol (Lausanne). 2021 Oct 28;12:760860. doi: 10.3389/fendo.2021.760860. eCollection 2021.

Nonalcoholic fatty liver disease (NAFLD) has become the most common chronic liver disease worldwide. A significant proportion of patients with NAFLD develop a progressive inflammatory condition termed nonalcoholic steatohepatitis (NASH), which may eventually advance to cirrhosis and hepatocellular carcinoma...

Cite
Hirsova P, Bamidele AO, Wang H, et al. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne). 2021;12:760860doi: 10.3389/fendo.2021.760860.
Hirsova, P., Bamidele, A. O., Wang, H., Povero, D., & Revelo, X. S. (2021). Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Frontiers in endocrinology, 12760860. https://doi.org/10.3389/fendo.2021.760860
Hirsova, Petra, et al. "Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma." Frontiers in endocrinology vol. 12 (2021): 760860. doi: https://doi.org/10.3389/fendo.2021.760860
Hirsova P, Bamidele AO, Wang H, Povero D, Revelo XS. Emerging Roles of T Cells in the Pathogenesis of Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Front Endocrinol (Lausanne). 2021 Oct 28;12:760860. doi: 10.3389/fendo.2021.760860. eCollection 2021. PMID: 34777255; PMCID: PMC8581300.
Copy Download .nbib Format: NLM
Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence.

Frontiers in medicine

Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ.
PMID: 34164419
Front Med (Lausanne). 2021 Jun 07;8:684151. doi: 10.3389/fmed.2021.684151. eCollection 2021.

Convalescent plasma has been used worldwide to treat patients hospitalized with coronavirus disease 2019 (COVID-19) and prevent disease progression. Despite global usage, uncertainty remains regarding plasma efficacy, as randomized controlled trials (RCTs) have provided divergent evidence regarding the survival...

Cite
Klassen SA, Senefeld JW, Senese KA, et al. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021;8:684151doi: 10.3389/fmed.2021.684151.
Klassen, S. A., Senefeld, J. W., Senese, K. A., Johnson, P. W., Wiggins, C. C., Baker, S. E., van Helmond, N., Bruno, K. A., Pirofski, L. A., Shoham, S., Grossman, B. J., Henderson, J. P., Wright, R. S., Fairweather, D., Paneth, N. S., Carter, R. E., Casadevall, A., & Joyner, M. J. (2021). Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Frontiers in medicine, 8684151. https://doi.org/10.3389/fmed.2021.684151
Klassen, Stephen A, et al. "Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence." Frontiers in medicine vol. 8 (2021): 684151. doi: https://doi.org/10.3389/fmed.2021.684151
Klassen SA, Senefeld JW, Senese KA, Johnson PW, Wiggins CC, Baker SE, van Helmond N, Bruno KA, Pirofski LA, Shoham S, Grossman BJ, Henderson JP, Wright RS, Fairweather D, Paneth NS, Carter RE, Casadevall A, Joyner MJ. Convalescent Plasma Therapy for COVID-19: A Graphical Mosaic of the Worldwide Evidence. Front Med (Lausanne). 2021 Jun 07;8:684151. doi: 10.3389/fmed.2021.684151. eCollection 2021. PMID: 34164419; PMCID: PMC8215127.
Copy Download .nbib Format: NLM
Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance.

Journal of the Endocrine Society

Adams JD, Treiber G, Hurtado MD, Laurenti MC, Dalla Man C, Cobelli C, Rizza RA, Vella A.
PMID: 30591957
J Endocr Soc. 2018 Nov 21;3(1):135-145. doi: 10.1210/js.2018-00222. eCollection 2019 Jan 01.

CONTEXT: In subjects with normal fasting glucose (NFG) and normal glucose tolerance (NGT), glucose concentrations >155 mg/dL 1 hour after 75 g of oral glucose predict increased risk of progression to diabetes. Recently, it has been suggested that the...

Cite
Adams JD, Treiber G, Hurtado MD, et al. Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance. J Endocr Soc. 2018;3(1):135-145doi: 10.1210/js.2018-00222.
Adams, J. D., Treiber, G., Hurtado, M. D., Laurenti, M. C., Dalla Man, C., Cobelli, C., Rizza, R. A., & Vella, A. (2019). Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance. Journal of the Endocrine Society, 3(1), 135-145. https://doi.org/10.1210/js.2018-00222
Adams, J D, et al. "Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance." Journal of the Endocrine Society vol. 3,1 (2019): 135-145. doi: https://doi.org/10.1210/js.2018-00222
Adams JD, Treiber G, Hurtado MD, Laurenti MC, Dalla Man C, Cobelli C, Rizza RA, Vella A. Increased Rates of Meal Absorption Do Not Explain Elevated 1-Hour Glucose in Subjects With Normal Glucose Tolerance. J Endocr Soc. 2018 Nov 21;3(1):135-145. doi: 10.1210/js.2018-00222. eCollection 2019 Jan 01. PMID: 30591957; PMCID: PMC6302905.
Copy Download .nbib Format: NLM
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study.

PLoS medicine

Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D.
PMID: 34928960
PLoS Med. 2021 Dec 20;18(12):e1003872. doi: 10.1371/journal.pmed.1003872. eCollection 2021 Dec.

BACKGROUND: The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized...

Cite
Senefeld JW, Johnson PW, Kunze KL, et al. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021;18(12):e1003872doi: 10.1371/journal.pmed.1003872.
Senefeld, J. W., Johnson, P. W., Kunze, K. L., Bloch, E. M., van Helmond, N., Golafshar, M. A., Klassen, S. A., Klompas, A. M., Sexton, M. A., Diaz Soto, J. C., Grossman, B. J., Tobian, A. A. R., Goel, R., Wiggins, C. C., Bruno, K. A., van Buskirk, C. M., Stubbs, J. R., Winters, J. L., Casadevall, A., Paneth, N. S., Shaz, B. H., Petersen, M. M., Sachais, B. S., Buras, M. R., Wieczorek, M. A., Russoniello, B., Dumont, L. J., Baker, S. E., Vassallo, R. R., Shepherd, J. R. A., Young, P. P., Verdun, N. C., Marks, P., Haley, N. R., Rea, R. F., Katz, L., Herasevich, V., Waxman, D. A., Whelan, E. R., Bergman, A., Clayburn, A. J., Grabowski, M. K., Larson, K. F., Ripoll, J. G., Andersen, K. J., Vogt, M. N. P., Dennis, J. J., Regimbal, R. J., Bauer, P. R., Blair, J. E., Buchholtz, Z. A., Pletsch, M. C., Wright, K., Greenshields, J. T., Joyner, M. J., Wright, R. S., Carter, R. E., & Fairweather, D. (2021). Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS medicine, 18(12), e1003872. https://doi.org/10.1371/journal.pmed.1003872
Senefeld, Jonathon W, et al. "Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study." PLoS medicine vol. 18,12 (2021): e1003872. doi: https://doi.org/10.1371/journal.pmed.1003872
Senefeld JW, Johnson PW, Kunze KL, Bloch EM, van Helmond N, Golafshar MA, Klassen SA, Klompas AM, Sexton MA, Diaz Soto JC, Grossman BJ, Tobian AAR, Goel R, Wiggins CC, Bruno KA, van Buskirk CM, Stubbs JR, Winters JL, Casadevall A, Paneth NS, Shaz BH, Petersen MM, Sachais BS, Buras MR, Wieczorek MA, Russoniello B, Dumont LJ, Baker SE, Vassallo RR, Shepherd JRA, Young PP, Verdun NC, Marks P, Haley NR, Rea RF, Katz L, Herasevich V, Waxman DA, Whelan ER, Bergman A, Clayburn AJ, Grabowski MK, Larson KF, Ripoll JG, Andersen KJ, Vogt MNP, Dennis JJ, Regimbal RJ, Bauer PR, Blair JE, Buchholtz ZA, Pletsch MC, Wright K, Greenshields JT, Joyner MJ, Wright RS, Carter RE, Fairweather D. Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study. PLoS Med. 2021 Dec 20;18(12):e1003872. doi: 10.1371/journal.pmed.1003872. eCollection 2021 Dec. PMID: 34928960; PMCID: PMC8730442.
Copy Download .nbib Format: NLM
A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets.

Science advances

Li Z, Schulze RJ, Weller SG, Krueger EW, Schott MB, Zhang X, Casey CA, Liu J, Stöckli J, James DE, McNiven MA.
PMID: 28028537
Sci Adv. 2016 Dec 16;2(12):e1601470. doi: 10.1126/sciadv.1601470. eCollection 2016 Dec.

The autophagic digestion of lipid droplets (LDs) through lipophagy is an essential process by which most cells catabolize lipids as an energy source. However, the cellular machinery used for the envelopment of LDs during autophagy is poorly understood. We...

Cite
Li Z, Schulze RJ, Weller SG, et al. A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets. Sci Adv. 2016;2(12):e1601470doi: 10.1126/sciadv.1601470.
Li, Z., Schulze, R. J., Weller, S. G., Krueger, E. W., Schott, M. B., Zhang, X., Casey, C. A., Liu, J., Stöckli, J., James, D. E., & McNiven, M. A. (2016). A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets. Science advances, 2(12), e1601470. https://doi.org/10.1126/sciadv.1601470
Li, Zhipeng, et al. "A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets." Science advances vol. 2,12 (2016): e1601470. doi: https://doi.org/10.1126/sciadv.1601470
Li Z, Schulze RJ, Weller SG, Krueger EW, Schott MB, Zhang X, Casey CA, Liu J, Stöckli J, James DE, McNiven MA. A novel Rab10-EHBP1-EHD2 complex essential for the autophagic engulfment of lipid droplets. Sci Adv. 2016 Dec 16;2(12):e1601470. doi: 10.1126/sciadv.1601470. eCollection 2016 Dec. PMID: 28028537; PMCID: PMC5161429.
Copy Download .nbib Format: NLM
Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment.

Frontiers in oncology

Scott CL, Becker MA, Haluska P, Samimi G.
PMID: 24363999
Front Oncol. 2013 Dec 04;3:295. doi: 10.3389/fonc.2013.00295.

Despite increasing evidence that precision therapy targeted to the molecular drivers of a cancer has the potential to improve clinical outcomes, high-grade epithelial ovarian cancer (OC) patients are currently treated without consideration of molecular phenotype, and predictive biomarkers that...

Cite
Scott CL, Becker MA, Haluska P, et al. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013;3:295doi: 10.3389/fonc.2013.00295.
Scott, C. L., Becker, M. A., Haluska, P., & Samimi, G. (2013). Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Frontiers in oncology, 3295. https://doi.org/10.3389/fonc.2013.00295
Scott, Clare L, et al. "Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment." Frontiers in oncology vol. 3 (2013): 295. doi: https://doi.org/10.3389/fonc.2013.00295
Scott CL, Becker MA, Haluska P, Samimi G. Patient-derived xenograft models to improve targeted therapy in epithelial ovarian cancer treatment. Front Oncol. 2013 Dec 04;3:295. doi: 10.3389/fonc.2013.00295. PMID: 24363999; PMCID: PMC3849703.
Copy Download .nbib Format: NLM
Showing 1 to 11 of 11 entries